- Home
- NMI vs VRCA Comparison
NMI vs VRCA Comparison
Compare NMI & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMI | VRCA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.5M | 137.3M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NMI | VRCA |
|---|---|---|
| Price | $10.76 | $6.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 19.3K | ★ 52.3K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $9.62 | $0.52 |
| 52 Week High | $11.18 | $9.82 |
Technical Indicators
Market Signals| Indicator | NMI | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 48.04 |
| Support Level | $9.88 | $5.20 |
| Resistance Level | $10.88 | $6.40 |
| Average True Range (ATR) | 0.23 | 0.50 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 57.25 | 49.25 |
Price Performance
Historical ComparisonAbout NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.